Key result
Everolimus-eluting stent reduces target vessel failure versus BMS and matches paclitaxel-eluting stent at 9 months.
Why the study?
Second-generation everolimus-eluting stents were approved based on clinical efficacy and safety data, but more head-to-head randomized controlled trials are needed to confirm their long-term safety and efficacy compared to first-generation DES and bare metal stents.
Does the everolimus-eluting stent improve outcomes compared to bare metal or paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention?
Does the everolimus-eluting stent improve outcomes compared to bare metal or paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
This review summarizes evidence from the SPIRIT trial program demonstrating the efficacy and safety of the everolimus-eluting stent compared to bare metal and paclitaxel-eluting stents.
Drug-eluting stents (DES) have had a major impact in interventional cardiology. Compared to bare metal stents, they significantly reduce restenosis and the need for target vessel revascularization. Four DES are available in the US, the first-generation sirolimus-eluting (Cypher ® ) and paclitaxel-eluting (Taxus ® ) stents and later approved second-generation everolimus-eluting (Xience V ® ) and zotarolimus-eluting (Endeavor ® ) stents. The Xience V stent was approved on the basis of clinical efficacy and safety data from 3 studies in the SPIRIT clinical trial program. Within this trial series, the Xience V was superior to its bare metal stent counterpart, the Vision® stent, and noninferior to the paclitaxel-eluting stent for target vessel failure at 9 months. This review provides a comprehensive assessment of the data derived from both the pre- and post-approval randomized controlled trials and registry studies of Xience V that comprise the SPIRIT clinical trial program including recently published mid-term outcomes. The implications of the results in terms of interventional practice will be discussed.
No takes yet. Share an insight, caveat, or question.
J. Dawn Abbott (2009) reported a review. Everolimus-eluting coronary stent (Xience V) vs. Bare metal stent (Vision) and paclitaxel-eluting stent was evaluated on Target vessel failure. The everolimus-eluting Xience V stent was superior to its bare metal counterpart and noninferior to the paclitaxel-eluting stent for target vessel failure at 9 months.
Synapse has enriched 10 related papers. Consider them for comparative context: